期刊
CANCERS
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cancers12061453
关键词
lncRNA; breast cancer; alternative splicing; estrogen receptor; RNA-Seq
类别
资金
- Associazione Italiana per la Ricerca sul Cancro [IG 15600]
- Fondazione CRT [2017.0823]
- University of Torino
DSCAM-AS1is a cancer-related long noncoding RNA with higher expression levels in Luminal A, B, and HER2-positive Breast Carcinoma (BC), where its expression is strongly dependent on Estrogen Receptor Alpha (ER alpha).DSCAM-AS1expression is analyzed in 30 public datasets and, additionally, by qRT-PCR in tumors from 93 BC patients, to uncover correlations with clinical data. Moreover, the effect of DSCAM-AS1 knockdown on gene expression and alternative splicing is studied by RNA-Seq in MCF-7 cells. We confirmDSCAM-AS1overexpression in high grade Luminal A, B, and HER2+ BCs and find a significant correlation with disease relapse. In total, 908 genes are regulated byDSCAM-AS1-silencing, primarily involved in the cell cycle and inflammatory response. Noteworthily, the analysis of alternative splicing and isoform regulation reveals 2085 splicing events regulated byDSCAM-AS1, enriched in alternative polyadenylation sites, 3 ' UTR (untranslated region) shortening and exon skipping events. Finally, theDSCAM-AS1-interacting splicing factor heterogeneous nuclear ribonucleoprotein L (hnRNPL) is predicted as the most enriched RBP for exon skipping and 3 ' UTR events. The relevance ofDSCAM-AS1overexpression in BC is confirmed by clinical data and further enhanced by its possible involvement in the regulation of RNA processing, which is emerging as one of the most important dysfunctions in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据